Specialty Pharma Journal Specialty, Precision & Technology
SANTA CLARA, Calif.–(BUSINESS WIRE)–Epidemiologists and genomics researchers who want to gain a deeper understanding of human genetic variation in translational research now have access to Thermo Fisher Scientific’s Axiom Precision Medicine Research Array, a powerful genotyping solution with more than 900,000 markers of biological significance for clinical research studies. The …
Tag Archives: precision medicine
July, 2016
-
7 July
FDA Advances Precision Medicine Initiative with Draft Guidances on NGS-Based Tests
In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration today issued two draft guidances that, when finalized, will provide a flexible and streamlined approach to the oversight of tests that detect medically important differences in a person’s genomic makeup. The powerful new technology, known as …
June, 2016
-
24 June
Mayo Clinic Introduces Precision Medicine in Psychiatry
ROCHESTER, Minn. — Mayo Clinic is highlighting the potential merits of using precision medicine in prescribing antidepressants. Details appear in the current issue of Mayo Clinic Proceedings. Eleven percent of Americans 12 years and older have been prescribed antidepressant medication, according to Centers for Disease Control and Prevention data from …
-
22 June
Waters Partners with Singapore’s BTI to Identify Cancer Markers
MILFORD, Mass.–(BUSINESS WIRE)–Waters Corporation (NYSE:WAT) today announced a joint effort with the Bioprocessing Technology Institute (BTI), a research institute within Singapore’s Agency for Science, Technology and Research (A*STAR), to develop new methods of finding cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. As …
-
13 June
IDMC Recommends Continuation of Argos Therapeutics Late-Stage RCC Study
DURHAM, N.C., June 13, 2016 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that the independent data monitoring committee (IDMC) for the Company’s pivotal Phase …
May, 2016
-
9 May
Immune Design and Gritstone Oncology Partner to Develop Personalized Immunotherapies
SEATTLE and SOUTH SAN FRANCISCO, Calif. and EMERYVILLE Calif,, May 09, 2016 (GLOBE NEWSWIRE) — Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, and Gritstone Oncology, a private cancer immunotherapy company developing next-generation, personalized cancer therapeutics, today announced a clinical collaboration for development of novel, personalized immunotherapies combining …
-
3 May
Foundation Medicine and AstraZeneca Partner to Develop Companion Diagnostic Assays in Oncology
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced an agreement with AstraZeneca to develop companion diagnostic assays to facilitate personalized medicine in oncology by identifying patients most likely to benefit from medicines within AstraZeneca’s oncology pipeline. “We use companion diagnostics throughout clinical development to deliver innovative, targeted therapies to patients …
April, 2016
-
29 April
New Gene Testing Technology Finds Cancer Risks ‘Hiding in Plain Sight’
A research team led by an award-winning genomicist at Western University has developed a new method for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate, but also increase the number of patients that …
-
29 April
Making Precision Medicine A Reality: Genomics Researchers Unveil Road Map to Disease Origin
TUCSON, Ariz. – Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies – thanks to work by three computational biology research teams from the University of Arizona Health Sciences, University …
-
22 April
AbbVie and CytomX Announce Collaboration for Probody Drug Conjugates
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV) and CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). CD71 is highly …